Accelerate Diagnostics Total Depreciation and Amortization - Cash Flow 2010-2024 | AXDX
Accelerate Diagnostics total depreciation and amortization - cash flow from 2010 to 2024. Total depreciation and amortization - cash flow can be defined as the total amount of depreciation and amortization listed on the Cash Flows Statement
| Accelerate Diagnostics Annual Total Depreciation and Amortization - Cash Flow (Millions of US $) |
|
|---|---|
| 2024 | $12 |
| 2023 | $8 |
| 2022 | $4 |
| 2021 | $14 |
| 2020 | $14 |
| 2019 | $12 |
| 2018 | $9 |
| 2017 | $3 |
| 2016 | $3 |
| 2015 | $2 |
| 2014 | $1 |
| 2013 | $0 |
| 2012 | $N/A |
| 2012 | $0 |
| 2011 | $0 |
| 2010 | $0 |
| 2009 | $0 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | MED INSTRUMENTS | $0.013B | $0.012B |
| Accelerate Diagnostics, Inc. is focused on developing and commercializing instrumentation for the rapid identification and antibiotic susceptibility testing of infectious pathogens. The company is developing BACcel(TM) system, a rapid diagnostic platform for diagnosis in life-threatening bacterial infections and OptiChem(R) surface coatings for use in micro arraying components. Accelerate Diagnostics Inc., formerly known as Accelr8 Technology Corp., is based in Denver, Colorado. | |||